I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 8 studies | 26% ± 11% | |
| naive B cell | 6 studies | 18% ± 2% | |
| B cell | 6 studies | 21% ± 6% | |
| natural killer cell | 5 studies | 29% ± 8% | |
| CD8-positive, alpha-beta T cell | 5 studies | 26% ± 7% | |
| plasmacytoid dendritic cell | 5 studies | 20% ± 5% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 4 studies | 18% ± 1% | |
| CD16-negative, CD56-bright natural killer cell, human | 4 studies | 24% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 30% ± 6% | |
| CD4-positive, alpha-beta T cell | 4 studies | 24% ± 5% | |
| classical monocyte | 4 studies | 20% ± 6% | |
| regulatory T cell | 4 studies | 22% ± 7% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
| effector memory CD8-positive, alpha-beta T cell | 3 studies | 23% ± 6% | |
| glomerular endothelial cell | 3 studies | 17% ± 1% | |
| mucosal invariant T cell | 3 studies | 17% ± 2% | |
| endothelial cell | 3 studies | 22% ± 4% | |
| oligodendrocyte precursor cell | 3 studies | 34% ± 15% | |
| endothelial cell of vascular tree | 3 studies | 25% ± 6% | |
| fibroblast | 3 studies | 20% ± 5% | |
| pericyte | 3 studies | 24% ± 6% |
